Heron Therapeutics | HRTX - Current Liabilities

Stock Price
1.20
Daily Change
-0.08 -5.91%
Monthly
-19.80%
Yearly
-28.01%
Q1 Forecast
2.71

Heron Therapeutics reported $89.71M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
ALKERMES USD 474.36M 31.6M Sep/2025
Alnylam Pharmaceuticals USD 1.56B 254.63M Sep/2025
Amarin USD 182.23M 3.71M Sep/2025
ANI Pharmaceuticals USD 270.56M 33.72M Sep/2025
Anika Therapeutics USD 19.09M 3.01M Sep/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Heron Therapeutics USD 89.71M 168.89M Sep/2025
Insmed USD 417.21M 105.53M Sep/2025
Ligand Pharmaceuticals USD 30.54M 34.2M Sep/2025
Merck USD 28.63B 2.59B Sep/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 107.08M 206.09M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Surmodics USD 20.54M 347K Sep/2024
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Veracyte USD 72.15M 4.28M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025